Balanced news tone
News Sentiment
DYAI sentiment intelligence
Dyadic International Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+12.7% over one week, +55.4% over four weeks, trend inactive, and near fair-value range.
Price to sales forward of Dyadic International, Inc. – NASDAQ:DYAI
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Price to sales forward of Dyadic International, Inc. – NASDAQ:DYAI
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:33
- Source
- TradingView
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 13:30
- Source
- simplywall.st
Dyadic International Q1 2026 Earnings: Continued Losses as Pre-Revenue Company Advances C1 Platform; Shares Rise 4.82% - Interim Report
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 09 Jul 2026 17:47
- Source
- dars.gov.et
Craig-Hallum Maintains Dyadic(DYAI.US) With Buy Rating
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 08 Jul 2026 19:48
- Source
- 富途牛牛
Dyadic International stock reflects a thin catalyst day. Focus stays on its enzyme platform.
Dyadic International (DYAI) stock is focused on its enzyme platform business, with no new catalysts reported. The company utilizes fungal expression and recombinant protein development for industrial and life-science applications. Its value is tied to platform development, licens
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 16:24
- Source
- AD HOC NEWS
Dyadic International Progresses Multiple Protein Production Partnerships
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 13:32
- Source
- MT Newswires
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 07 Jul 2026 11:25
- Source
- GlobeNewswire
Dyadic says its C1 platform can make antibodies and vaccines faster
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 11:25
- Source
- Stock Titan
DYAI - Dyadic International Inc, DE Forecast, Target Price
This article provides a detailed financial overview of Dyadic International Inc (DYAI), including key metrics such as market capitalization, income, sales, EPS, and various performance indicators. It also lists the last closing price, daily change, and a target price set at $6.00
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 06 Jul 2026 13:47
- Source
- Finviz
Francisco Trust sells $343,763 in Dyadic International shares By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 11:07
- Source
- Investing.com Nigeria
Francisco Trust (DYAI) amends large convertible note and sells DYADIC shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 10:30
- Source
- Stock Titan
DYADIC International (NASDAQ: DYAI) trustee reports 11.58% stake in 13G/A
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Jul 2026 07:00
- Source
- Stock Titan
Form 4 Dyadic International Inc For: 6 July By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- Investing.com Nigeria
Dyadic International Receives Japan Patent Allowance for Recombinant Protein Expression Technology
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 12:13
- Source
- MT Newswires
Dyadic Expands IP Protection and Business Development Activities in Japan
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 29 Jun 2026 11:25
- Source
- GlobeNewswire
Japan backs Dyadic’s protein technology as it courts partners
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Stock Titan
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 12:46
- Source
- TMX Newsfile
Dyadic (NASDAQ: DYAI) investors OK reverse split, pay plan and auditor
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
Nasdaq warns Dyadic (NASDAQ: DYAI) over bid price and listing shortfalls
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 11:25
- Source
- GlobeNewswire
[8-K] DYADIC INTERNATIONAL INC Reports Material Event | DYAI 8-K Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Dyadic (DYAI) Q1 2026 Earnings Call Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jun 2026 16:39
- Source
- Motley Fool
DYAI - Dyadic International Inc, DE Stock Price and Quote
This article provides a detailed stock quote and financial overview for Dyadic International Inc (DYAI), a healthcare biotechnology company. It includes key financial metrics, recent news headlines, analyst ratings, and insider transaction data. The company's stock closed at $0.8
- Tone
- Positive 67/100
- Event
- Analyst action
- Published
- 30 May 2026 23:09
- Source
- Finviz
Dyadic and Scripps Research Partner to Accelerate Hantavirus Antibody and Vaccine Development Using C1 Biologic Platform
Dyadic International, Inc. and Scripps Research have announced a collaboration to develop monoclonal antibody and vaccine candidates for hantaviruses, including the Andes virus, using Dyadic’s C1 protein production platform. This partnership aims to address the urgent need for ra
- Tone
- Positive 71/100
- Event
- Deals and strategy
- Published
- 29 May 2026 10:08
- Source
- Minichart
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 11:25
- Source
- GlobeNewswire
Skyline Corporate Communications Group, LLC Announces
Skyline Corporate Communications Group, LLC announced that Dyadic International, Inc. (Nasdaq: DYAI), operating as Dyadic Applied BioSolutions, will present at the Skyline Signature Series™ on Wednesday, May 27, 2026, at 12:00 PM ET. This live, interactive online event invites in
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 24 May 2026 13:10
- Source
- GlobeNewswire
Dyadic International Inc. (DYAI) Q1 2026 Earnings: Wider Loss as R&D Investment Accelerates, Stock Rises on Pipeline Hope - Short-Term Outlook
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 23 May 2026 07:00
- Source
- DonanımHaber
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 20:05
- Source
- GlobeNewswire
Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 19:45
- Source
- GlobeNewswire